Full-Time
Software Engineer
Frontend
Posted on 10/7/2025
Pattern Bioscience
51-200 employees
AI-driven rapid bacterial ID and AST
No salary listed
Pune, Maharashtra, India
Hybrid
Hybrid position.
 Software Engineering (1) |
|---|
- 3+ years of experience in building applications based on JavaScript
- Strong understanding and practical experience of JavaScript, HTML, CSS3 and component driven UI development.
- Experience in building JavaScript applications with modern client-side structured React.js JS frameworks
- Proficiency with SVN or Git and appreciation for clean and well documented code
- Experience of working with developers within an agile development process to ensure a polished and easy-to-use end product
- Proven analytical/technical aptitude with excellent problem-solving skills
- Leadership experience in coaching, mentoring and knowledge transfer
- Excellent communication, presentation and facilitation skills
- Ability to work under tight deadlines and handle multiple/detail-oriented tasks.
- Understanding of memory management in JavaScript
- Experience with Webpack, Typescript, Ruby/Rails
- AWS platform experience
- Familiarity with D3 or Graph/Charting Libraries
- 1+ years’ experience with eCommerce platforms
- Collaborate with team of full stack and frontend developers to design/architect, develop, and maintain progressive web-based applications
- Participate in brainstorming sessions and contribute ideas to our technology, algorithms and products
- Work with the product and design teams to understand end-user requirements, formulate use cases, and then translate that into a pragmatic and effective technical solution
- Manage and prioritize within timelines for project milestones and take personal responsibility for on-time deliverables
- Troubleshoot, debug, performance-tune, and optimize a module of code
- Communicate technical concepts with tradeoffs, risks and benefits
- Continually focus on individual and team member development
Pattern Bioscience develops rapid clinical diagnostics that identify bacterial infections and determine antibiotic resistance. Its system uses single-cell analysis with AI pattern recognition to deliver definitive ID/AST results in about four hours. The product suite includes diagnostic devices, consumables, service contracts, and software for AI analysis. By speeding and improving accuracy, Pattern Bioscience aims to help hospitals reduce inappropriate antibiotic use and combat antibiotic resistance.
Company Size
51-200
Company Stage
Series D
Total Funding
$91.6M
Headquarters
Austin, Texas
Founded
2016
Simplify's Take
What believers are saying
- $43M Series D funding from AMR Action Fund supports FDA 510(k) submission.
- $40.9M BARDA contract accelerates pneumonia and bacteremia panel development.
- Over 1,000 samples enrolled in multi-center trial for Q3 regulatory push.
What critics are saying
- Accelerate Diagnostics' PhenoVue captures market with FDA-cleared 3-hour AST.
- BioFire's FilmArray dominates ICU syndromic testing, sidelining single-pathogen focus.
- Clinical trial failure by mid-2026 exhausts Series D runway, halting launch.
What makes Pattern Bioscience unique
- Digital CultureTM enables culture-free phenotypic ID/AST in four hours.
- Single-cell analysis captures all resistance mechanisms unlike genotypic tests.
- Pneumonia ID/AST Panel targets critically ill patients with FDA Breakthrough Designation.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Health Insurance
Dental Insurance
Vision Insurance
Life Insurance
Unlimited Paid Time Off
Paid Holidays
401(k) Company Match
401(k) Retirement Plan
Health Savings Account/Flexible Spending Account
Growth & Insights and Company News
6 month growth
↑ 1%1 year growth
↑ 2%2 year growth
↓ -1%Pattern Bioscience has raised $43 million in Series D funding, led by AMR Action Fund, Illumina Ventures, and Omnimed Capital. The funds will support a US multi-center clinical trial and regulatory submission for their Pneumonia ID/AST Panel, which has FDA Breakthrough Device Designation and is backed by a BARDA contract worth up to $40.9 million. Latham & Watkins LLP represented Pattern Bioscience in the transaction.
To quickly develop effective treatments for drug-resistant bacterial infections, Pattern is a leader in the application of single-cell microbiology.
Pattern Bioscience secures $28.7 million in Series C financing to accelerate development of first-of-its-kind infectious disease diagnostic platform
Pattern Bioscience, an Austin, TX-based company which specializes in rapid diagnosis and antibiotic susceptibility testing (AST) for bacterial infections, raised $28.7M in Series C funding.
Including the Series C round, Pattern has now raised $68 million to date, the company said in a statement.